International Journal of Antimicrobial Agents

Sensational artemisinin-piperaquine for treatment of COVID-19 in prospect

Retrieved on: 
星期三, 十一月 3, 2021
People, Coronavirus, Research, Artemisinin, National Medical Products Administration, Guangzhou University, Guangzhou Medical University, Disease, Association, Tablet, Firestone Institute for Respiratory Health, Guangzhou University of Chinese Medicine, Infection, Joint Medical Service (Germany), TCM, Efficacy, National Health Commission, Genetics, Malaria, Hospital, Social media, International Journal of Antimicrobial Agents, COVID-19, Safety, Antimicrobial, Xinhui People's Hospital, Observation, Artemisia annua, Treatment, Canadian International Council, Pharmaceutical industry

These drugs first came to the industry's attention after the International Journal of Antimicrobial Agents published a paper titled "Safety and Efficacy of Artemisinin-Piperaquine for Treatment of COVID-19".

Key Points: 
  • These drugs first came to the industry's attention after the International Journal of Antimicrobial Agents published a paper titled "Safety and Efficacy of Artemisinin-Piperaquine for Treatment of COVID-19".
  • This implies how the scientific community and the general public are in desperate need of effective drug treatments for COVID-19.
  • And they have been the drug of first choice recommended by the National Health Commission of China since 2009.
  • Going ahead, the drug is expected to have a greater role to play in the treatment of other diseases," said Zhu Layi, president of Guangdong New South Group.

Shionogi to Present In Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETCROJA® (cefiderocol) Against Gram-Negative Pathogens

Retrieved on: 
星期三, 九月 29, 2021
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Benchmark, Serratia marcescens, Mortality, CNS, Pyelonephritis, Infection, Antimicrobial, Research, Antibacterial activity, 2021 Essex County Council election, AMPC, Degenerative disease, Escherichia coli, Central nervous system disease, Urinary tract infection, Health, Collection, Intention, FDA, Patient, Gastroenterology, Bacteria, Marketing, Antimicrobial Agents and Chemotherapy, CEO, Canadian International Council, Medicine, Esbly, Pseudomonas aeruginosa, Pain, Serine, Cell membrane, International Journal of Antimicrobial Agents, Gram-negative bacteria, Klebsiella pneumoniae, Penicillin-binding proteins, Cutis laxa, Tillotson, Cell, Abstract (summary), Enzyme, Treatment, Pharmaceutical industry, Medical device, Vaccine, FETCROJA® (cefiderocol), Shionogi, FETCROJA® (CEFIDEROCOL), SHIONOGI

Shionogi & Co., Ltd. (hereafter Shionogi) today announces that 11 abstracts on FETCROJA (cefiderocol) will be shared at IDWeek.

Key Points: 
  • Shionogi & Co., Ltd. (hereafter Shionogi) today announces that 11 abstracts on FETCROJA (cefiderocol) will be shared at IDWeek.
  • Abstracts will be available in the IDWeek Interactive Program and include:
    Poster #1058: In Vitro and in Vivo Antibacterial Activity of Cefiderocol against Burkholderia spp.
  • Cefiderocol is a siderophore cephalosporin antibiotic with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore.
  • Shionogi has a strong heritage in the field of anti-infectives and has been developing antimicrobial therapies for more than 60 years.